GLOW

Home › Research › GLOW

View GLOW in the AxYn range →

Snapshot

Chemistry and make-up

Glow is a blend, not a molecule: three separate peptides co-lyophilised in one vial. There is no official or pharmacopoeial standard ratio; the widely marketed example is roughly 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 = 70 mg total (5:1:1, GHK-Cu weighted highest) (Peptide Partners 70 mg Glow; BioLongevity Labs Glow) [D]. Because ratios vary by vendor, a reputable supplier should define its own spec (component masses, ratio, total load) and hold suppliers to it rather than accepting “Glow” as if it were standardised.

Component notes that matter for QC:

• GHK-Cu is a copper(II) complex of the tripeptide Gly-His-Lys; the copper is part of the identity, so the CoA should confirm copper content/complexation, not just the peptide. GHK free base is ~340.4 g/mol; the 1:1 copper complex is ~400-402 g/mol (PubChem verified 2026-07-30) [B]. It is blue/teal in solution, which can mask visual assessment of the other two peptides.
• BPC-157 ships as free base, acetate or arginate; salt form changes MW and effective peptide content (see `bpc-157.md`).
• TB-500 is the category’s biggest identity trap: “TB-500” can be the ~889 Da fragment or full ~4963 Da Tβ4 (see `tb-500.md`). In a blend this ambiguity is hidden unless the CoA reports each component’s mass by MS.

So a Glow CoA is only meaningful if it resolves three identities and three loads independently.

What it is studied for (evidence)

There is essentially no blend-specific human (or even animal) trial data for Glow. Any evidence is the sum of the single-component literature, and combining peptides does not transfer or multiply their individual evidence. Refer to the component files:

• GHK-Cu: skin remodelling, collagen/ECM signalling, antioxidant and wound-healing activity, mostly in vitro and cosmetic/dermatology contexts. (See a dedicated GHK-Cu profile; largely preclinical/cosmetic [A/D].)
• BPC-157: large rodent tendon/muscle/gut repair body of work, very limited human data (see `bpc-157.md`) [A].
• TB-500 / Tβ4: actin-sequestering, cell-migration and wound-healing mechanism; human trial data exists mainly for topical ocular Tβ4, not systemic musculoskeletal use (see `tb-500.md`) [A].
• Marketing claims vs data: vendors present Glow as a synergistic “injury + skin glow” stack with dosing charts. No controlled study demonstrates synergy or any human outcome for the combination. Synergy is a marketing assertion, not a finding.
• Human clinical status: none for the blend.

Handling, format and stability

Supplied lyophilised; reconstituted with bacteriostatic water for research handling (no dosing guidance here). Store lyophilised cold and protected from light; reconstituted material is cold-chain dependent and less stable. Blends add a stability wrinkle: the three peptides can degrade at different rates, and the copper in GHK-Cu is redox-active and could in principle promote oxidation of the other components, so real-time/accelerated stability data on the finished blend is more informative than component data alone.

Regulatory and trade status

• UK/EU RUO: research use only; not a medicine. Keep all listings/emails strictly research-use; healing/beauty claims risk medicinal-by-presentation classification.
• WADA (sport): prohibited. The blend contains TB-500 (Tβ4), which is banned at all times under S2, so Glow inherits WADA-prohibited status regardless of the other components. BPC-157 (non-approved) adds S0 exposure. Treat Glow as banned in sport (WADA Prohibited List) [B].
• US: compounding status of the components moved in 2026. On 23 July 2026 the PCAC voted to recommend BPC-157 and TB-500 (both 8-6, 1 abstention) for the 503A bulks list, over FDA staff objection, but these are advisory recommendations only, not rules, and still need FDA rulemaking. GHK-Cu is a separate track: it was removed from the interim 503A lists in April 2026 and awaits a later PCAC consult (before Feb 2027). Either way the blend itself is not an approved product and AxYn sells it strictly research use only.
• Customs: multi-peptide blends attract QC scrutiny because identity/load is harder to verify.

Sources

• [B] PubChem: GHK-Cu CID 165429100 / GHK CID 73587; BPC-157 CID 9941957; Tβ4 CID 45382195 — https://pubchem.ncbi.nlm.nih.gov
• [B] WADA Prohibited List (S2 covers TB-500/Tβ4) — https://www.wada-ama.org/en/prohibited-list
• [A] Component evidence: see `bpc-157.md` and `tb-500.md` source lists (Tβ4 dry-eye RCTs, BPC-157 reviews)
• [D] Vendor blend listings/ratios (Peptide Partners, BioLongevity Labs, Parahealth) — commercial; source of the 50/10/10 example and dosing charts we do not use — https://peptide.partners/product/glow-blend-bpc-157-tb-500-ghk-cu/

Plain summary

Glow is a three-peptide repair blend (GHK-Cu + BPC-157 + TB-500), commonly sold as a 70 mg vial at roughly a 50/10/10 ratio, but there is no standard ratio so a reputable supplier should define and lock its own spec. There is no human or blend-specific trial evidence for Glow itself; its story is just the (mostly preclinical) evidence of its parts, and any “synergy” claim is marketing. Because it contains TB-500 it is banned in sport (WADA S2), and its CoA is only meaningful if it proves each component’s identity and load separately rather than quoting one blended purity number.

For laboratory and research use only (RUO). Not for human or veterinary use, not for consumption, and not a medicine. Information is a research summary, not medical advice, and contains no dosing guidance.

For laboratory research use only. Not for human or veterinary use, not for consumption, and not a medicine. This is a research summary, not medical advice, and contains no dosing guidance.